August 24, 2017 / 5:16 AM / 5 months ago

Roche says FDA grants priority review to haemophilia drug emicizumab

ZURICH, Aug 24 (Reuters) - Swiss pharma group Roche said the U.S. Food and Drug Administration (FDA) granted priority review to its emicizumab for haemophilia A with inhibitors.

The application is based on positive results of a phase III study in adolescents and adults with haemophilia A with inhibitors and interim phase III results in children, Roche said in a statement on Thursday.

The FDA is expected to make a decision on approval by February 23, 2018, Roche said, adding that nearly a third of haemophilia A patients developed inhibitors limiting treatment options and increasing the risk of life-threatening bleeds. (Reporting by Silke Koltrowitz; editing by Brenna Hughes Neghaiwi)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below